Remove 2014 Remove Healthcare Remove Leads
article thumbnail

[Podcast] Is Your Healthcare Email Marketing HIPAA Compliant?

Healthcare Success

Most healthcare marketers are unaware that seemingly innocuous patient email marketing campaigns are yet another area where you could inadvertently run afoul with HIPAA regulations, or, even worse, suffer a breach. From the moment someone interacts with your healthcare organization, you must inform them of your communication methods (e.g.,

article thumbnail

Developing an effective contamination control strategy

European Pharmaceutical Review

The panelists referred to other documents that are useful for CCS development: the 2014 Pharmaceutical Healthcare Sciences Society (PHSS) Technical Monograph No 20 Bio-Contamination 2 as well as the Parenteral Drug Association (PDA) Technical Report 90: Contamination Control Strategy Development, 3 published in February 2023.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novel haemophilia B gene therapy approved

European Pharmaceutical Review

Pfizer licensed BEQVEZ from Spark Therapeutics in December 2014. BEQVEZ is currently being reviewed by the European Medicines Agency (EMA), Pfizer confirmed. Article: The evolution of AAVs in cell and gene therapy The post Novel haemophilia B gene therapy approved appeared first on European Pharmaceutical Review.

article thumbnail

Tributes as former NICE, MHRA chair Sir Mike Rawlins dies

pharmaphorum

The UK healthcare sector is mourning one of the most eminent of its figures in the last few decades – Professor Sir Mike Rawlins – who has passed away at the age of 81. ” The post Tributes as former NICE, MHRA chair Sir Mike Rawlins dies appeared first on.

article thumbnail

PhRMA lies to protect pharma profits

World of DTC Marketing

He leads the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital in Boston. Data were mainly accessible for smaller firms, products in some therapeutic regions, orphan drugs, first-in-class drugs, therapeutic agents that received accelerated approval, and products between 2014 and 2018.

Pharma 255
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

While that sounds encouraging, most cancer drugs launched between 2009 and 2014 cost more than USD 100,000 annually. This leads to a question; “where does it end?” For DTC, the model will become one of collaboration with patients as they help them navigate the complex system of American healthcare.

Pharma 210
article thumbnail

The U.S. health insurance market is undergoing a post-pandemic sea change

Clarivate

Insurance exchanges underwent their largest single-year enrollment growth since their inception in 2014, pushing exchange enrollment to yet another all-time high. This may also lead to gaps in care, reduced drug adherence, increased emergency room visits and a decline in chronic care management. The post The U.S.